Ovarian cancer
Results
Phase 2
This trial looked at a second course of olaparib for women with ovarian cancer that had come back after having had platinum chemotherapy and olaparib. It was for women who had a gene change () in or .
It was open to women whose ovarian cancer is one of the following:
These cancers are treated in the same way, so when we use the term ovarian cancer in this summary, we are referring to all 3.
The trial was open for people to join between 2017 and 2019. The team published the results in 2023.
Recruitment start: 26 May 2017
Recruitment end: 9 September 2019
Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.
Professor Gordon Jayson
AstraZeneca
The Christie NHS Foundation Trust
Manchester Academic Health Science Centre Trials co-ordination unit (MAHSC-CTU)
Last reviewed: 11 Sept 2023
CRUK internal database number: 14574
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
